Open an account

Iperionx

IPX · ASX

$12.44−$0.38 (−2.96%)TodayMarket closed ·
Prev close $12.82

About IPX

IperionX Ltd. engages in the development of low carbon titanium for advanced industries, including space, aerospace, electric vehicles and 3D printing. The company is headquartered in Charlotte, North Carolina. The company went IPO on 2018-04-16. The company is engaged in the exploration and evaluation of its mineral properties in the United States and the research, development, and commercialization of its associated metals technologies to support an integrated titanium processing operation. The company holds a 100% interest in the Titan Project, covering more than 10,000 acres of mineral properties in Tennessee, United States, which consider prospective for critical minerals including titanium, rare earth elements, silica sand and zircon. Its titanium metal and critical minerals are essential for advanced United States industries including space, aerospace, defense, consumer electronics, hydrogen, electric vehicles and additive manufacturing.

Employees
30
Headquarters
Charlotte, North Carolina
Listed
Apr 16, 2018
Sector
Materials
Industry
Metals & Mining
Website
iperionx.com

IPX key statistics

Market cap
677.39M
Price-earnings ratio
0.00
Dividend yield
—
Average volume
302.88K
Volume
208.44K
Open price
$12.54
High today
$12.66
Low today
$12.14
52 Week high
$61.45
52 Week low
$12.68

Iperionx (IPX) at a glance

Iperionx (IPX) last traded at $12.44, with a market cap of 677.39M and a price-to-earnings ratio of 0.00.

Today the stock has traded between $12.14 and $12.66. The current price is 2.5% above the day's low and 1.7% below its high.

Volume so far is 208.44K shares, below the average of 302.88K shares a day.

Over the past year Iperionx has ranged from $12.68 to $61.45, and now sits 0% of the way up that range.

The average analyst price target is $53.85, 332.8% above the current price, from 5 recent ratings.

Analyst ratings

Latest rating from each analyst over the past 12 months

100%of 5 analyst ratings say Buy
  • Buy100.0%
  • Hold0.0%
  • Sell0.0%
Price target · 3 analystsAvg $53.85
Low
$40.35
Now
$12.44
High
$68.91

IPX news

  • Avi Kapoor

    Concentrix Posts Mixed Q3 Results, Joins Cal-Maine Foods And Other Big Stocks Moving Lower In Wednesday’s Pre-Market Session

  • Press releaseBusiness Wire

    IPX Investors Have Opportunity to Join IperionX Limited Fraud Investigation with SBS Law

  • Press releasePRNewswire

    Tungsten Reshoring Goes Public: Western Star Files DIBC Application as APT Prices Surge ~900% YoY and the U.S. Defense Procurement Cliff Closes In

  • Press releaseBusiness Wire

    Securities Fraud Investigation Into IperionX Limited (IPX) Continues – Shareholders Who Lost Money Urged To Contact The Law Offices of Frank R. Cruz

  • Press releaseBusiness Wire

    Securities Fraud Investigation Into IperionX Limited (IPX) Continues – Shareholders Who Lost Money Urged To Contact Glancy Prongay Wolke & Rotter LLP, a Leading Securities Fraud Law Firm

  • Press releasePRNewswire

    Small Ohio Company's Chemistry Breakthrough Could Have Major Defense Implications

  • Press releaseBusiness Wire

    Securities Fraud Investigation Into IperionX Limited (IPX) Announced – Shareholders Who Lost Money Urged To Contact Glancy Prongay Wolke & Rotter LLP, a Leading Securities Fraud Law Firm

  • Press releaseBusiness Wire

    IperionX Limited (IPX) Shareholders Who Lost Money – Contact Law Offices of Howard G. Smith About Securities Fraud Investigation

Similar companies

Companies in the same industry as Iperionx

Most active stocks

Highest trading volume today

Newly listed

Companies that went public in the past six weeks

Information on this page is provided for informational purposes only and is not a recommendation to buy, sell or hold any security. Investing involves risk, including possible loss of principal. Market data is delayed at least 15 minutes and is provided without warranty. Analyst ratings, price targets and company data come from third-party sources. Past performance does not guarantee future results.